Home > Healthcare > Pharmaceuticals > Clinical Nutrition > Intravenous Solutions Market

Intravenous Solutions Market Analysis

  • Report ID: GMI8359
  • Published Date: Mar 2024
  • Report Format: PDF

Intravenous Solutions Market Analysis

Based on type, the global market is classified into total parenteral nutrition (TPN) and peripheral parenteral nutrition (PPN). The total parenteral nutrition type dominated the market with revenue of USD 8.7 billion in 2023.

 

  • Total parenteral nutrition (TPN) is a comprehensive method for delivering a wide range of nutrients intravenously. TPN solutions are composed of a balanced mix of nutrients, including carbohydrates, proteins, fats, vitamins, and minerals, tailored to meet the specific nutritional needs of each patient. TPN plays a critical role in providing complete nutrition to patients who cannot consume food orally.

     

  • The increasing prevalence of chronic diseases, such as cancer and gastrointestinal disorders, which often result in malnutrition and require specialized nutrition support is driving the demand for TPN solutions.

     

  • Additionally, advancements in TPN formulations and administration techniques, along with the rising geriatric population globally, are further contributing to the segment's high market share.

 

Intravenous Solutions Market, By Composition (2023)

Based on composition, the intravenous solutions market is classified into carbohydrates, vitamins & minerals, single-dose amino acids, parenteral lipid emulsion, and other compositions. The single-dose amino acids segment was valued at USD 4.1 billion 2023.

 

  • Amino acids play a crucial role in parenteral nutrition, providing essential nutrients for patients who cannot consume food orally.

     

  • Additionally, the rising demand for specialized nutrition formulations is boosting the segmental growth.

     

  • The segment's growth is also supported by technological advancements in intravenous delivery systems, which have improved the safety and efficacy of administering amino acids intravenously.

     

  • Thus, the convenience and ease of use of single-dose amino acid solutions have made them a preferred choice among healthcare providers, further driving their market share.

     

Based on age group, the intravenous solutions market is classified into pediatric, adult, and geriatric. The pediatric segment is expected to hold the highest revenue throughout the forecast period.

 

  • The rising incidence of pediatric diseases and conditions requiring intravenous therapy, such as dehydration, infections, and chronic illnesses, is a significant driver of market growth. This trend is particularly pronounced in emerging economies where access to healthcare is improving, leading to greater diagnosis and treatment of pediatric conditions.

     

  • Governments and healthcare organizations are allocating greater resources towards pediatric healthcare services, including intravenous therapy, leading to increased investment in pediatric IV solutions. This trend is observed globally, with rising healthcare expenditure on pediatric care contributing to market growth in both developed and developing countries.

     

Based on application, the intravenous solutions market is classified into nutritional support, blood transfusion, fluid & electrolyte balance, and other applications. The nutritional support segment held the highest business share of 38.8% in 2023.

 

  • Nutritional support plays a crucial role in the management of critically ill patients in intensive care units (ICUs). Healthcare providers increasingly recognize the importance of early initiation of parenteral nutrition in critically ill patients to mitigate the risk of malnutrition and improve clinical outcomes. This focus on nutritional support in critical care settings drives the demand for intravenous solutions tailored for this patient population.

     

  • Further, as the global population ages, there is a greater prevalence of age-related conditions such as malnutrition, sarcopenia, and dysphagia. Elderly patients require intravenous nutritional support to maintain adequate nutrient intake and prevent complications associated with malnutrition, contributing to the growth of the market.

     

Based on end-user, the IV solutions market is classified into hospitals and clinics, ambulatory surgery centers, and home care settings. The hospitals and clinics segment is expected to hold the highest revenue throughout the forecast period.

 

  • The increasing number of surgical procedures performed in hospitals and clinics is driving the demand for intravenous solutions for perioperative care. Intravenous fluids and medications are commonly used during surgery to maintain fluid balance, manage pain, and prevent complications, contributing to the growth of intravenous solutions in hospitals and clinics.

 

North America Intravenous Solutions Market, 2020 – 2032 (USD Billion)

In 2023, North America held a market share of 42.7% in the global intravenous solutions market and is expected to dominate throughout the forecast period.

 

  • High regional market growth can be attributed to the advanced healthcare infrastructure in the region, a strong focus on patient care, and high healthcare expenditure, all contributing to the demand for IV solutions.

     

  • Moreover, increasing surgical procedures, rising prevalence of cancer, and the growing trend of home healthcare also contribute to the high market share of North America in the IV solutions market.

     
  • For instance, as per the data published by the Centers for Disease Control and Prevention, cancer ranks as the second leading cause of death in the U.S. Approximately one in four deaths in the country is attributed to cancer.

     

  • Additionally, the presence of prominent market players and extensive research and development activities in the region, further drive market expansion.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Intravenous solutions industry size was USD 13 billion in 2023 and is expected to reach USD 24.8 billion by 2032, driven by the growing geriatric population, increasing cases of malnutrition, and high prevalence of preterm births.

The total parenteral nutrition type segment reached a revenue of USD 8.7 billion in 2023 and will grow significantly through 2032, due to its role in providing complete nutrition to patients who cannot consume food orally.

North America recorded 42.7% of the intravenous solutions industry share in 2023 and is expected to dominate throughout 2024 and 2032 attributed to the advanced healthcare infrastructure in the region, a strong focus on patient care, and high healthcare expenditure.

Ajinomoto Co., Inc., Amanta Healthcare, Axa Parenterals Ltd, B. Braun Melsungen AG, Baxter International Inc., Fresenius Kabi USA, LLC, Grifols, S.A., ICU Medical. Inc., JW Life Science, Otsuka Pharmaceutical Co., Ltd, and Pfizer, Inc.

Intravenous Solutions Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 11
  • Tables & Figures: 310
  • Countries covered: 20
  • Pages: 180
 Download Free Sample